Cited by 2,409Glioma Diagnosis and TreatmentMedical Imaging Techniques and ApplicationsOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Response criteria for phase II studies of supratentorial malignant glioma.

Macdonald, D R, Cascino, T L, Schold, S C, Cairncross, J G·1990·Journal of Clinical Oncology

DOI 10.1200/jco.1990.8.7.1277

Open this paper in CoChat — free account

Abstract

We suggest "new" response criteria for phase II studies of supratentorial malignant glioma and favor rigorous criteria similar to those in medical oncology, with important modifications. Four response categories are proposed: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Response in this scheme is based on major changes in tumor size on the enhanced computed tomographic (CT) or magnetic resonance imaging (MRI) scan. Scan changes are interpreted in light of steroid use and neurologic findings. We advocate careful patient selection, emphasize pitfalls in the assessment of response, and suggest guidelines to minimize misinterpretations of response.

Integrity signals

Registry

Crossref · 10.1200/jco.1990.8.7.1277

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Successful chemotherapy for recurrent malignant oligodendroglioma
Cairncross, J. G., & Macdonald, D. R. (1988) · Annals of Neurology · doi:10.1002/ana.410230408 · Cited by 345
Self-citation
Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors
Levin, V. A., Crafts, D. C., Norman, D. M., Hoffer, P. B., Spire, J., & Wilson, C. B. (1977) · Journal of neurosurgery · doi:10.3171/jns.1977.47.3.0329 · Cited by 199
Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.
Surbone, A., Longo, D. L., Vt, D., Ihde, D. C., Duffey, P. L., Jaffe, E. S., Solomon, D., HUBBARD, S. M., & Young, R. C. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.12.1832 · Cited by 178
Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response.
Warr, D. G., McKinney, S., & Tannock, I. F. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.9.1040 · Cited by 151
Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas
Chamberlain, M. C., Murovic, J. A., & Levin, V. A. (1988) · Neurology · doi:10.1212/wnl.38.9.1371 · Cited by 149
Steroid‐induced CT changes in patients with recurrent malignant glioma
Cairncross, J. G., Macdonald, D. R., Pexman, J. H. W., & Ives, F. J. (1988) · Neurology · doi:10.1212/wnl.38.5.724 · Cited by 100
Self-citation
Computerized tomography in the prognosis of malignant cerebral gliomas
Murovic, J. A., Turowski, K., Wilson, C. B., Hoshino, T., & Levin, V. A. (1986) · Journal of neurosurgery · doi:10.3171/jns.1986.65.6.0799 · Cited by 42
Criteria and definitions for response and relapse in children with brain tumors
Zeltzer, P. M., Friedman, H. S., Norris, D. G., & Ragab, A. H. (1985) · Cancer · doi:10.1002/1097-0142(19851001)56:7+ · Cited by 35
Post-Surgical Contrast Enhancement Mimicking Residual Brain Tumour
Cairncross, J. G., Pexman, J. H. W., & Rathbone, M. P. (1985) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100046643 · Cited by 33
Self-citation
The accuracy of volumetric measurement of high-grade gliomas
Chisholm, R. A., Stenning, S. P., & Hawkins, T. D. (1989) · Clinical Radiology · doi:10.1016/s0009-9260(89)80007-8 · Cited by 32

Flagged first, then by citations

Show all 11 references

Sorted by citations

Items 501–600 of 1,001

Anaplastic astrocytoma in adults
Stupp, R., Reni, M., Gatta, G., Mazza, E. A., & Vecht, C. J. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.03.003 · Cited by 100
Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma
Kong, D., Lee, J.-I., Kim, J. H., Kim, S. T., Kim, W. S., Suh, Y., Dong, S. M., & Nam, D. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop030 · Cited by 100
Interobserver variability in the radiological assessment of response to chemotherapy in glioma
Vos, M. J., Uitdehaag, B. M. J., Barkhof, F., Heimans, J. J., Baayen, H., Boogerd, W. J., Castelijns, J. A., Elkhuizen, P. H. M., & Postma, T. J. (2003) · Neurology · doi:10.1212/01.wnl.0000049467.54667.92 · Cited by 99
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
Brandes, A. A., Tosoni, A., Franceschi, E., Blatt, V., Santoro, A., Faedi, M., Amistà, P., Gardiman, M. P., Labianca, R., Bianchini, C., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0926-8 · Cited by 99
Treatment of Elderly Patients With Glioblastoma
Zarnett, O. J., Sahgal, A., Gosio, J., Perry, J., Berger, M. S., Chang, S. M., & Das, S. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.3739 · Cited by 100
Conventional and advanced magnetic resonance imaging in patients with high-grade glioma
Pope, W. B., & Brandal, G. (2018) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.18.03086-8 · Cited by 106
Early metabolic responses in temozolomide treated low-grade glioma patients
Wyss, M. T., Höfer, S., Bruehlmeier, M., Hefti, M., Uhlmann, C., Bärtschi, E., Buettner, U. W., & Roelcke, U. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9896-2 · Cited by 98
Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study.
Jeremic, B. M., Grujičić, D., Jevremovic, S., Stanisavljevic, B., Milojevic, L., Djuric, L. J., & Mijatovic, L. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1074 · Cited by 98
Objective response rate assessment in oncology: Current situation and future expectations
Aykan, N. F., & Özatlı, T. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i2.53 · Cited by 97
Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors
Lassman, A. B., Hoang‐Xuan, K., Polley, M. C., Brandes, A. A., Cairncross, J. G., Kros, J. M., Ashby, L. S., TAPHOORN, M. J. B., Souhami, L., Dinjens, W. N. M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02543 · Cited by 104
Self-citation
Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status
Romano, A., Calabria, L. F., Tavanti, F., Minniti, G. C., Rossi‐Espagnet, M. C., Coppola, V., Pugliese, S., Guida, D., Francione, G., Colonnese, C., et al. (2012) · European Radiology · doi:10.1007/s00330-012-2601-4 · Cited by 97
High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison
Tanaka, M., Ino, Y., Nakagawa, K., Tago, M., & Todo, T. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70395-8 · Cited by 97
Glioblastoma: A Method for Predicting Response to Antiangiogenic Chemotherapy by Using MR Perfusion Imaging—Pilot Study
Sawlani, R. N., Raizer, J. J., Horowitz, S. W., Shin, W., Grimm, S. A., Chandler, J. P., Levy, R. M., Getch, C. C., & Carroll, T. (2010) · Radiology · doi:10.1148/radiol.10091341 · Cited by 97
Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma
Nagane, M., Nishikawa, R., Narita, Y., Kobayashi, H., Takano, S., Shinoura, N., Aoki, T., Sugiyama, K., Kuratsu, J., Muragaki, Y., et al. (2012) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hys121 · Cited by 97
Primary central nervous system lymphoma in Japan
Hayakawa, T., Takakura, K., Abe, H., Yoshimoto, T., Tanaka, R., Sugita, K., Kikuchi, H., Uozumi, T., Hori, T., Fukui, H., et al. (1994) · Journal of Neuro-Oncology · doi:10.1007/bf01053274 · Cited by 97
Linear accelerator-based stereotactic radiosurgery in recurrent glioblastoma: A single center experience
Şirin, S., Oysul, K., Sürenkök, S., Sağer, Ö., Dinçoğlan, F., Dırıcan, B., & Beyzadeoğlu, M. (2011) · Vojnosanitetski pregled · doi:10.2298/vsp1111961s · Cited by 96
Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: a systematic review
Koekkoek, J. A. F., Kerkhof, M., Dirven, L., Heimans, J. J., Reijneveld, J. C., & TAPHOORN, M. J. B. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov032 · Cited by 96
High-grade Gliomas
Nayak, L., & Reardon, D. A. (2017) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000554 · Cited by 100
Volumetry of [11C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme
Galldiks, N., Ullrich, R. T., Schroeter, M., Fink, G. R., & Kracht, L. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1219-5 · Cited by 96
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF
Chauffert, B., Feuvret, L., Bonnetain, F., Taillandier, L., Frappaz, D., Taillia, H., Schött, R., Honnorat, J., Fabbro, M., Tennevet, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu148 · Cited by 99
Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma
Chamberlain, M. C. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0741-z · Cited by 96
Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival
Hattingen, E., Jurcoane, A., Daneshvar, K., Pilatus, U., Mittelbronn, M. G. A., Steinbach, J. P., & Bähr, O. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not105 · Cited by 96
Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in korea
Kong, D., Nam, D., Kang, S.-H., Lee, J. W., Chang, J. H., Kim, J.-H., Lim, Y.-J., Koh, Y.-C., Chung, Y.-G., Kim, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12273 · Cited by 97
Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study
Schumacher, T., Höfer, S., Eichhorn, K., Wasner, M., Zimmerer, S., Freitag, P., Probst, A., Gratzl, O., Reubi, J. C., Maëcke, H. R., et al. (2002) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-001-0717-x · Cited by 96
Quantitative T1 and T2 mapping in recurrent glioblastomas under bevacizumab: earlier detection of tumor progression compared to conventional MRI
Lescher, S., Jurcoane, A., Veit, A., Bähr, O., Deichmann, R., & Hattingen, E. (2014) · Neuroradiology · doi:10.1007/s00234-014-1445-9 · Cited by 95
Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours
Jenkinson, M. D., Smith, T. S., Joyce, K. A., Fildes, D., Broome, J. C., du Plessis, D., Haylock, B. J., Husband, D. J., Warnke, P. C., & Walker, C. A. (2006) · Neuroradiology · doi:10.1007/s00234-006-0122-z · Cited by 95
Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study
Chabot, P., Hsia, T., Ryu, J., Горбунова, В. А., Belda-Iniesta, C., Ball, D., Kio, E. A., Mehta, M. P., Papp, K., Qin, Q., et al. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2275-x · Cited by 95
Recommendations of the brain tumor subcommittee for the reporting of trials
Gnekow, A. K. (1995) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950240209 · Cited by 95
Somatic mutations associated with MRI-derived volumetric features in glioblastoma
Gutman, D. A., Dunn, W. D., Großmann, P., Cooper, L., Holder, C. A., Ligon, K. L., Alexander, B. M., & Aerts, H. J. W. L. (2015) · Neuroradiology · doi:10.1007/s00234-015-1576-7 · Cited by 94
Dendritic Cell Therapy of High‐Grade Gliomas
Gool, S. V., Maes, W., Ardon, H., Verschuere, T., Cauter, S. V., & Vleeschouwer, S. D. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00316.x · Cited by 94
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma
Verhoeff, J. J. C., Lavini, C., Linde, M. E. V., Stalpers, L. J. A., Majoie, C. B. L. M., Reijneveld, J. C., van Furth, W. R., & Richel, D. J. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp591 · Cited by 94
Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma
Raizer, J. J., RADEMAKER, A. W., Evens, A. M., Rice, L., Schwartz, M. A., Chandler, J. P., Getch, C. C., Tellez, C., & Grimm, S. A. (2011) · Cancer · doi:10.1002/cncr.26709 · Cited by 94
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide
Gerstner, E. R., Eichler, A. F., Plotkin, S. R., Drappatz, J., Doyle, C. L., Xu, L., Duda, D. G., Wen, P. Y., Jain, R. K., & Batchelor, T. T. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0390-7 · Cited by 94
The importance of surgical resection in malignant glioma
Stummer, W., & Kamp, M. A. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283320165 · Cited by 94
CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin’s lymphoma
Bessell, E. M., Graus, F., López‐Guillermo, A., Villà, S., Verger, E., Petit, J., Holland, I. M., & Byrne, P. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01451-1 · Cited by 93
Adult medulloblastoma: Multiagent chemotherapy
Greenberg, H. S., Chamberlain, M. C., Glantz, M., & Wang, S. (2001) · Neuro-Oncology · doi:10.1093/neuonc/3.1.29 · Cited by 93
Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker
Jain, R., Scarpace, L. M., Ellika, S., Torcuator, R., Schultz, L. R., Hearshen, D., & Mikkelsen, T. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9981-6 · Cited by 92
A phase I/II trial of vandetanib for patients with recurrent malignant glioma
Kreisl, T. N., McNeill, K. A., Sul, J., Iwamoto, F. M., Shih, J. H., & Fine, H. A. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos265 · Cited by 92
High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma
Chamberlain, M. C., & Johnston, S. K. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq011 · Cited by 92
True Progression versus Pseudoprogression in the Treatment of Glioblastomas: A Comparison Study of Normalized Cerebral Blood Volume and Apparent Diffusion Coefficient by Histogram Analysis
Song, Y. S., Choi, S. H., Park, C., Yi, K. S., Lee, W. J., Yun, T. J., Kim, T. M., Lee, S., Kim, J., Sohn, C., et al. (2013) · Korean Journal of Radiology · doi:10.3348/kjr.2013.14.4.662 · Cited by 92
Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials
Lombardi, G., Pambuku, A., Bellu, L., Farina, M., Puppa, A. D., Denaro, L., & Zagonel, V. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.018 · Cited by 92
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma
Reardon, D. A., Norden, A. D., Desjardins, A., Vredenburgh, J. J., Herndon, J. E., Sykes, A. D., Sampson, J. H., Gururangan, S., Peters, K. B., McLendon, R. E., et al. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0687-1 · Cited by 92
Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life
Maschio, M. C. E., Dinapoli, L., Sperati, F., Pace, A., Fabi, A., Vidiri, A., & Muti, P. C. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0460-x · Cited by 92
Hypofractionated stereotactic radiotherapy for the treatment of brain metastases
Kwon, A., DiBiase, S. J., Wang, B., Hughes, S., Milcarek, B. I., & Zhu, Y. (2009) · Cancer · doi:10.1002/cncr.24082 · Cited by 92
Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs
Chang, S. M., Kuhn, J. G., Wen, P. Y., Greenberg, H. S., Schiff, D., Conrad, C. A., Fink, K., Robins, H. I., Cloughesy, T. F., DeAngelis, L. M., et al. (2004) · Investigational New Drugs · doi:10.1023/b:drug.0000036685.72140.03 · Cited by 92
Pituitary Adenoma Volumetry with 3D Slicer
Egger, J., Kapur, T., Nimsky, C., & Kikinis, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051788 · Cited by 91
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma
Norden, A. D., Lesser, G. J., Drappatz, J., Ligon, K. L., Hammond, S. N., Lee, E. Q., Reardon, D., Fadul, C. E., Plotkin, S. R., Batchelor, T. T., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not040 · Cited by 91
Enhanced chemotherapy delivery by intraarterial infusion and blood‐brain barrier disruption in the treatment of cerebral metastasis
Fortin, D., Gendron, C., Boudrias, M., & Lapointe‐Garant, M. (2007) · Cancer · doi:10.1002/cncr.22450 · Cited by 91
Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma
Ernst‐Stecken, A., Ganslandt, O., Lambrecht, U., Sauer, R., & Grabenbauer, G. G. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9231-0 · Cited by 91
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma
Reardon, D. A., Egorin, M. J., Desjardins, A., Vredenburgh, J. J., Beumer, J. H., Lagattuta, T. F., Gururangan, S., Herndon, J. E., Salvado, A. J., & Friedman, H. S. (2009) · Cancer · doi:10.1002/cncr.24213 · Cited by 91
Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: A phase II study
Brandes, A. A., Ermani, M., Basso, U., Amistà, P., Berti, F., Scienza, R., Rotilio, A., Pinna, G. D., Gardiman, M. P., & Monfardini, S. (2001) · Annals of Oncology · doi:10.1023/a:1008336732273 · Cited by 91
Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13—PE38QQR for recurrent malignant glioma
Parney, I. F., Kunwar, S., McDermott, M., Berger, M. S., Prados, M. D., Cha, S., Croteau, D. J., Puri, R. K., & Chang, S. M. (2005) · Journal of neurosurgery · doi:10.3171/jns.2005.102.2.0267 · Cited by 91
Therapeutic potential of anticancer immunotoxins
Choudhary, S., Mathew, M., & Verma, R. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.04.003 · Cited by 90
Second surgery for recurrent glioblastoma: A concise overview of the current literature
Montemurro, N., Perrini, P., Blanco, M. O., & Vannozzi, R. (2016) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2016.01.010 · Cited by 90
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma
Wen, P. Y., Omuro, A. M. P., Ahluwalia, M. S., Fathallah‐Shaykh, H. M., Mohile, N. A., Lager, J. J., Laird, A., Tang, J., Jiang, J., Égile, C., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov083 · Cited by 94
Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas
Pouratian, N., Gasco, J., Sherman, J. H., Shaffrey, M. E., & Schiff, D. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9280-4 · Cited by 90
A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro‐Oncologia
Brandes, A. A., Cavallo, G., Reni, M., Tosoni, A., Nicolardi, L., Scopece, L., Franceschi, E., Sotti, G., Talacchi, A., Turazzi, S., et al. (2005) · Cancer · doi:10.1002/cncr.21110 · Cited by 90
Feasibility of Using Bevacizumab With Radiation Therapy and Temozolomide in Newly Diagnosed High-Grade Glioma
Narayana, A., Golfinos, J. G., Fischer, I., Raza, S., Kelly, P., Parker, E. C., Knopp, E. A., Medabalmi, P., Zagzag, D., Eagan, P., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.05.062 · Cited by 90
Quality of life in low-grade glioma patients receiving temozolomide
Liu, R., Solheim, K. N., Polley, M. C., Lamborn, K. R., Page, M., Fedoroff, A., Rabbitt, J. E., Butowski, N. A., Prados, M. D., & Chang, S. M. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-063 · Cited by 90
Response of radiochemotherapy-associated cerebral edema to a phytotherapeutic agent, H15
Streffer, J. R., Bitzer, M., Schabet, M., DICHGANS, J., & Weller, M. (2001) · Neurology · doi:10.1212/wnl.56.9.1219 · Cited by 90
Brain tumour post-treatment imaging and treatment-related complications
Kessler, A., & Bhatt, A. A. (2018) · Insights into Imaging · doi:10.1007/s13244-018-0661-y · Cited by 89
Updates in IDH-Wildtype Glioblastoma
Melhem, J. M., Detsky, J. S., Lim-Fat, M. J., & Perry, J. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01251-6 · Cited by 101
Natural history and management of brainstem gliomas in adults
Salmaggi, A., Fariselli, L., Milanesi, I. M., Lamperti, E., Silvani, A., Bizzi, A., Maccagnano, E., Trevisan, E., Laguzzi, E., Rudà, R., et al. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0589-0 · Cited by 89
Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up
Hb, N., Scott, S., & Volpi, C. (2004) · British Journal of Neurosurgery · doi:10.1080/02688690400012392 · Cited by 89
Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma
Zuniga, R. M., Torcuator, R., Jain, R., Anderson, J. E., Doyle, T. J., Schultz, L. R., & Mikkelsen, T. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0121-0 · Cited by 89
Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas
Triebels, V. H. J. M., TAPHOORN, M. J. B., Brandes, A. A., Menten, J. J., Frénay, M., Tosoni, A., Kros, J. M., Stege, E. M. B., Enting, R. H., Allgeier, A., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000137049.65631.db · Cited by 89
Prospective Analysis of Parametric Response Map–Derived MRI Biomarkers: Identification of Early and Distinct Glioma Response Patterns Not Predicted by Standard Radiographic Assessment
Galbán, C. J., Chenevert, T. L., Meyer, C. R., Tsien, C. I., Lawrence, T. S., Hamstra, D. A., Junck, L., Sundgren, P. C., Johnson, T. D., Galbán, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2098 · Cited by 88
Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis
López, P. D. D., Riñones‐Mena, E., & Corrales-García, E. M. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1816-x · Cited by 90
Salvage chemotherapy for recurrent spinal cord ependymona
Chamberlain, M. C. (2002) · Cancer · doi:10.1002/cncr.10826 · Cited by 88
Relationship between volume, dose and local control in stereotactic radiosurgery of brain metastasis
Molenaar, R., Wiggenraad, R. G. J., Kanter, A. V.-D., Walchenbach, R., & Vecht, C. J. (2009) · British Journal of Neurosurgery · doi:10.1080/02688690902755613 · Cited by 88
Volumetric and MGMT parameters in glioblastoma patients: Survival analysis
Iliadis, G., Kotoula, V., Chatzisotiriou, A., Televantou, D., Eleftheraki, A. G., Lambaki, S., Misailidou, D., Selviaridis, P., & Fountzilas, G. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-3 · Cited by 88
Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas
IWAMOTO, F. M., Hottinger, A. F., Karimi, S., Riedel, E., Dantis, J., Jahdi, M., Panageas, K., Lassman, A. B., Abrey, L. E., Fleisher, M., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor117 · Cited by 88
Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
Levin, V. A., Uhm, J. H., Jaeckle, K. A., Choucair, A. K., Flynn, P. J., Yung, W. K. A., Prados, M. D., Bruner, J. M., Chang, S., Kyritsis, A. P., et al. (2000) · PubMed · Cited by 88
Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI
Nelson, S. J. (2011) · NMR in Biomedicine · doi:10.1002/nbm.1669 · Cited by 87
Age and Radiation Response in Glioblastoma Multiforme
Barker, F. G., Chang, S. M., Larson, D. A., Sneed, P. K., Wara, W. M., Wilson, C. B., & Prados, M. D. (2001) · Neurosurgery · doi:10.1097/00006123-200112000-00002 · Cited by 87
A novel tool to analyze MRI recurrence patterns in glioblastoma
Wick, W., Stupp, R., Beule, A.-C., Bromberg, J. E. C., Wick, A., Ernemann, U., Platten, M., Marosi, C., Mason, W. P., van den Bent, M. J., et al. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-058 · Cited by 87
Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution
Michaelsen, S. R., Christensen, I. J., Grunnet, K., Stockhausen, M., Broholm, H., Kosteljanetz, M., & Poulsen, H. S. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-402 · Cited by 87
Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188-Re in adult recurrent high-grade glioma
Casacó, A., López, G., García, I., Rodríguez, J. A., Fernández, R., Figueredo, J., Torres, L. A., Pintado, A. P., Batista, J. F., Montaña, R. L., et al. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.3.5414 · Cited by 87
The management of histologically unverified presumed cerebral gliomas with radiotherapy
Rajan, B., Pickuth, D., Ashley, S., Traish, D., Monro, P., Elyan, S., & Brada, M. (1994) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(94)90064-7 · Cited by 87
Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma.
Grossman, S. A., Wharam, M. D., Sheidler, V. R., Kleinberg, L. R., Zeltzman, M., Yue, N. C., & Piantadosi, S. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2596 · Cited by 87
Phase I Study of Vandetanib With Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma
Drappatz, J., Norden, A. D., Wong, E. T., Doherty, L. M., LaFrankie, D. C., Ciampa, A. S., Kesari, S., Sceppa, C., Gerard, M., Phan, P., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.07.1741 · Cited by 86
Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science
Hochberg, F. H., Atai, N. A., Gonda, D. D., Hughes, M. S., Mawejje, B., Balaj, L., & Carter, R. S. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.905202 · Cited by 86
The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response
D’Alessandris, Q. G., Biffoni, M., Martini, M., Runci, D., Buccarelli, M., Cenci, T., Signore, M., Stancato, L. F., Olivi, A., Maria, R. D., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now304 · Cited by 87
Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort
Pallud, J., Audureau, É., Noël, G., Corns, R. A., Lechapt, E., Duntze, J., Pavlov, V., Guyotat, J., Hieu, P. D., Reste, P. L., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov126 · Cited by 90
First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Allen, B. G., Bodeker, K. L., Smith, M. C., Monga, V., Sandhu, S., Hohl, R. J., Carlisle, T. L., Brown, H. A., Hollenbeck, N. J., Vollstedt, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0594 · Cited by 89
Challenges with defining response to antitumor agents in pediatric neuro-oncology: A report from the response assessment in pediatric neuro-oncology (RAPNO) working group
Warren, K. E., Poussaint, T. Y., Vézina, G., Hargrave, D. R., Packer, R. J., Goldman, S., Wen, P. Y., Pollack, I. F., Zurakowski, D., Kun, L. E., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24562 · Cited by 85
Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010
Nava, F., Tramacere, I., Fittipaldo, V. A., Bruzzone, M. G., DiMeco, F., Fariselli, L., Finocchiaro, G., Pollo, B., Salmaggi, A., Silvani, A., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not316 · Cited by 85
Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy
Reardon, D. A., Wen, P. Y., Desjardins, A., Batchelor, T. T., & Vredenburgh, J. J. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.4.541 · Cited by 87
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
Khan, R. B. (2002) · Neuro-Oncology · doi:10.1215/15228517-4-1-39 · Cited by 85
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma
Raymond, É., Fabbro, M., Boige, V., Rixe, O., Frénay, M., Vassal, G., Faivre, S. J., Sicard, E., Germa, C., Rodier, J. M., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg159 · Cited by 85
Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma
Gerstein, J., Franz, K., Steinbach, J. P., Seifert, V., Fraunholz, I. B., Weiß, C., & Rödel, C. M. (2010) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2010.06.014 · Cited by 84
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
Melguizo, C., Prados, J. C., González, B., Ortíz, R., Concha, Á., Alvarez, P. J., Madeddu, R., Perazzoli, G., Oliver, J. A., López, R., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-250 · Cited by 84
Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
Hainsworth, J. D., Shih, K. C., Shepard, G. C., Tillinghast, G. W., Brinker, B. T., & Spigel, D. R. (2012) · PubMed · Cited by 84
Adult medulloblastoma
Herrlinger, U., Steinbrecher, A., Rieger, J., Hau, P., Kortmann, R., Meyermann, R., Schabet, M., BAMBERG, M., DICHGANS, J., Bogdahn, U., et al. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0560-2 · Cited by 84
Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme
Chua, S. L. L., Rosenthal, M. A., Wong, S., Ashley, D. M., Woods, A.-M., DOWLING, A. J., & Cher, L. (2004) · Neuro-Oncology · doi:10.1215/s1152851703000188 · Cited by 84
Procarbazine and High-Dose Tamoxifen as a Second-Line Regimen in Recurrent High-Grade Gliomas: A Phase II Study
Brandes, A. A., Ermani, M., Turazzi, S., Scelzi, E., Berti, F., Amistà, P., Rotilio, A., Licata, C., & Fiorentino, M. V. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.645 · Cited by 84
Intratumoral Doxorubicin in Patients With Malignant Brain Gliomas
Voulgaris, S., Partheni, M., Karamouzis, M. V., Dimopoulos, P., Papadakis, N., & Kalofonos, H. P. (2002) · American Journal of Clinical Oncology · doi:10.1097/00000421-200202000-00013 · Cited by 84
Primary central nervous system non-hodgkin’s lymphoma (PCNSL): survival advantages with combined initial therapy? a final report of the north central cancer treatment group (NCCTG) study 86-72-52
O’Neill, B. P., Wang, C.-H., & O'Fallon, J. R. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00450-7 · Cited by 84
A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma
Pan, E., Yu, D., Yue, B., Potthast, L., Chowdhary, S. A., Smith, P. S., & Chamberlain, M. C. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0943-z · Cited by 83
Discriminating Survival Outcomes in Patients with Glioblastoma Using a Simulation-Based, Patient-Specific Response Metric
Neal, M. L., Trister, A. D., Cloke, T., Sodt, R., Ahn, S., Baldock, A. L., Bridge, C. A., Lai, A., Cloughesy, T. F., Mrugała, M. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0051951 · Cited by 83

Authors: Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G.
Affiliations: Western University (CA)
ORCID: Cairncross, J G
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 1990-07
Volume: 8
Issue: 7
Pages: 1277-1280
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.1990.8.7.1277
OpenAlex: W1959628099
Cited by: 2,409
References: 11
Citations by year: 2026: 31 · 2025: 21 · 2024: 36 · 2023: 52 · 2022: 53 · 2021: 59 · 2020: 68 · 2019: 75 · 2018: 97 · 2017: 111 · 2016: 125 · 2015: 122 · 2014: 161 · 2013: 186 · 2012: 145
FWCI: 3.90
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: high-grade glioma, supratentorial glioma, response criteria, tumor size measurement, complete response, partial response, stable disease, progressive disease, steroid use, neurologic findings, patient selection, magnetic resonance imaging, computed tomography
MeSH terms: Diagnostic Errors, Drug Evaluation, Glioma, Humans, Magnetic Resonance Imaging, Medical Oncology, Tomography, X-Ray Computed, Supratentorial Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Response criteria for phase II studies of supratentorial malignant glioma.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks